Sorin has decided to invest US$8 million in West Bridgewater, MA-based Cardiosolutions, an early-stage company focused on the development of an innovative percutaneous system to treat patients with moderate-to-severe mitral valve regurgitation. The investment, which also includes an option to acquire the company in the future, will finance on-going product development and clinical testing of the technology.
Cardiosolutionsâ technology consists of a catheter delivery system and an implantable device, the Mitra-Spacer. The device is designed to fill the void created by a dilated valvular annulus or deteriorating valve mechanism. By providing a sealing surface for the leaflets of the diseased mitral valve, the implant reduces the mitral regurgitation in patients. According to Sorin, the "cutting-edge" technology represents a less invasive and percutaneous option for patients who suffer from moderate to severe mitral regurgitation, including a portion of those who have congestive heart failure.
At present, between 2 and 3 per cent of the worldâs population suffers from mitral regurgitation, with approximately 2.3 million patients in the US and Europe suffering from the most severe form. Every year some 500,000 new patients are diagnosed with the disease, of which over 80 per cent are untreated. For a substantial group of patients, surgery is not an option because they are high risk and many others delay treatment due to moderate symptoms.